Equities research analysts expect La Jolla Pharmaceutical (NASDAQ:LJPC) to post earnings of ($1.06) per share for the current quarter, Zacks Investment Research reports. Three analysts have provided estimates for La Jolla Pharmaceutical’s earnings, with the highest EPS estimate coming in at ($1.03) and the lowest estimate coming in at ($1.09). La Jolla Pharmaceutical reported earnings per share of ($1.73) in the same quarter last year, which suggests a positive year over year growth rate of 38.7%. The company is scheduled to report its next earnings results on Monday, March 2nd.
According to Zacks, analysts expect that La Jolla Pharmaceutical will report full-year earnings of ($4.44) per share for the current fiscal year, with EPS estimates ranging from ($4.50) to ($4.40). For the next year, analysts anticipate that the company will report earnings of ($2.90) per share, with EPS estimates ranging from ($3.75) to ($1.92). Zacks’ EPS averages are an average based on a survey of research analysts that follow La Jolla Pharmaceutical.
La Jolla Pharmaceutical (NASDAQ:LJPC) last issued its earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($1.08) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.05) by ($0.03). La Jolla Pharmaceutical had a negative return on equity of 2,032.71% and a negative net margin of 683.88%. The firm had revenue of $5.71 million during the quarter, compared to the consensus estimate of $6.96 million.
Shares of LJPC opened at $6.02 on Wednesday. The stock has a market cap of $170.99 million, a P/E ratio of -0.77 and a beta of 2.07. La Jolla Pharmaceutical has a 12-month low of $5.01 and a 12-month high of $16.44. The business’s fifty day moving average is $7.96 and its 200 day moving average is $8.55.
A number of institutional investors have recently modified their holdings of LJPC. Sio Capital Management LLC bought a new stake in La Jolla Pharmaceutical in the 2nd quarter valued at $12,121,000. Boxer Capital LLC bought a new position in shares of La Jolla Pharmaceutical during the 2nd quarter worth about $5,319,000. SG Americas Securities LLC lifted its holdings in shares of La Jolla Pharmaceutical by 394.8% during the 3rd quarter. SG Americas Securities LLC now owns 375,986 shares of the biopharmaceutical company’s stock worth $3,309,000 after acquiring an additional 299,995 shares during the period. VHCP Management III LLC lifted its holdings in shares of La Jolla Pharmaceutical by 24.7% during the 2nd quarter. VHCP Management III LLC now owns 1,251,898 shares of the biopharmaceutical company’s stock worth $11,580,000 after acquiring an additional 248,298 shares during the period. Finally, Rock Springs Capital Management LP lifted its holdings in shares of La Jolla Pharmaceutical by 53.3% during the 2nd quarter. Rock Springs Capital Management LP now owns 425,000 shares of the biopharmaceutical company’s stock worth $3,931,000 after acquiring an additional 147,764 shares during the period.
About La Jolla Pharmaceutical
La Jolla Pharmaceutical Company, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for life-threatening diseases. The company offers GIAPREZA (angiotensin II), an injection for intravenous infusion indicated to increase blood pressure in adults with septic or other distributive shock.
Featured Article: Key terms to understand channel trading
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for La Jolla Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for La Jolla Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.